BTAI - BioXcel Therapeutics, Inc.

Stock Grade Analysis

General Rating

C
Overall Score: 2/5
Multi-dimensional Scores
DCF: 1/5 ROE: 5/5 ROA: 1/5 D/E: 1/5 P/E: 1/5
Financial Ratios Trend

Grades Consensus

0

Strong Buy

8

Buy

6

Hold

1

Sell

0

Strong Sell

Buy

Consensus

Grade News & Updates

Date Grading Company New Grade Previous Grade Action Price When Posted News Title Publisher
2025-08-15 H.C. Wainwright Buy Buy Hold $4.98 BioXcel Therapeutics price target raised to $10 from $8 at … TheFly
2025-06-23 H.C. Wainwright Buy Buy Hold $1.65 BioXcel Therapeutics target adjusted to $8 from $3 at H.C. … TheFly
2024-10-21 H.C. Wainwright Buy Buy Hold $0.5659 BioXcel Therapeutics (BTAI) PT Lowered to $5 at H.C. Wainwr… StreetInsider
2024-09-06 H.C. Wainwright Buy Buy Hold $0.5901 H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeuti… StreetInsider
2024-04-15 H.C. Wainwright Buy Buy Hold $2.9 BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainw… StreetInsider
2023-08-15 Wells Fargo Buy Buy Hold $4.33 NVIDIA To Rally More Than 23%? Here Are 10 Other Analyst Fo… Benzinga
2023-05-26 Goldman Sachs Neutral Neutral Hold $N/A Goldman Sachs Maintains Neutral Rating for BioXcel Therapeu… Benzinga
2023-03-21 Piper Sandler Buy Buy Hold $19.79 Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst… Benzinga
2023-03-10 Oppenheimer Outperform N/A Initialise $20.68 Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2… Benzinga
2023-03-10 JonesTrading Buy N/A Initialise $20.68 Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2… Benzinga